Osimertinib induced adverse cardiac events: a case report.
作者信息
Lu Shang-Xin, Xing Yun-Li, Miao Ye, Zhang Xiao-Jie, Li Hong-Wei
机构信息
Department of Geriatrics, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Radiology Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
出版信息
J Geriatr Cardiol. 2023 Sep 28;20(9):702-706. doi: 10.26599/1671-5411.2023.09.006.
Abstract
摘要
相似文献
1
Osimertinib induced adverse cardiac events: a case report.奥希替尼诱发的不良心脏事件：一例报告
J Geriatr Cardiol. 2023 Sep 28;20(9):702-706. doi: 10.26599/1671-5411.2023.09.006.
2
Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).奥希替尼所致心脏毒性：对美国食品药品监督管理局不良事件报告系统（FAERS）的回顾性分析
JACC CardioOncol. 2019 Dec 17;1(2):172-178. doi: 10.1016/j.jaccao.2019.10.006. eCollection 2019 Dec.
3
Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.奥莫替尼有效减轻 EGFR L858R 突变型非小细胞肺癌病例联合奥希替尼致心脏毒性的临床症状：病例报告和综述。
Front Endocrinol (Lausanne). 2022 May 23;13:833929. doi: 10.3389/fendo.2022.833929. eCollection 2022.
4
Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.奥希替尼致晚期肺腺癌患者心力衰竭及 QT 间期延长。
J Oncol Pharm Pract. 2022 Jun;28(4):989-994. doi: 10.1177/10781552211073823. Epub 2022 Jan 17.
5
Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer.奥希替尼治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌患者时出现的全血细胞减少症
Onco Targets Ther. 2022 Apr 11;15:407-410. doi: 10.2147/OTT.S315385. eCollection 2022.
6
Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report.奥希替尼治疗非小细胞肺癌所致肠道出血和结肠炎：一例报告
Front Pharmacol. 2022 Apr 5;13:854277. doi: 10.3389/fphar.2022.854277. eCollection 2022.
7
Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis.奥希替尼引起的红细胞增多症相关急性下肢动脉血栓形成。
Am J Case Rep. 2021 Sep 7;22:e932252. doi: 10.12659/AJCR.932252.
8
[Pulmonary manifestations induced by osimertinib].[奥希替尼引起的肺部表现]
Rev Mal Respir. 2022 Jan;39(1):62-66. doi: 10.1016/j.rmr.2021.12.002. Epub 2021 Dec 27.
9
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma.病例报告：一名表皮生长因子受体（EGFR）突变的肺腺癌患者在使用帕博利珠单抗后序贯使用奥希替尼引发的史蒂文斯-约翰逊综合征和肝毒性。
Front Pharmacol. 2021 Aug 12;12:672233. doi: 10.3389/fphar.2021.672233. eCollection 2021.
10
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.真实世界的奥希替尼不良事件报告系统（FAERS）药物警戒研究
Sci Rep. 2022 Nov 15;12(1):19555. doi: 10.1038/s41598-022-23834-1.
引用本文的文献
1
Real-World Data on Osimertinib-Associated Cardiac Toxicity.奥希替尼相关心脏毒性的真实世界数据。
J Clin Med. 2025 Mar 5;14(5):1754. doi: 10.3390/jcm14051754.
本文引用的文献
1
Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report.奥希替尼治疗肺腺癌后发生致命性室性心律失常：一例报告
J Geriatr Cardiol. 2023 Mar 28;20(3):242-246. doi: 10.26599/1671-5411.2023.03.009.
2
Case Report: Torsade de Pointes Induced by the Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Osimertinib Combined With Litsea Cubeba.病例报告：第三代表皮生长因子受体酪氨酸激酶抑制剂奥希替尼联合山苍子导致尖端扭转型室性心动过速
Front Cardiovasc Med. 2022 May 31;9:903354. doi: 10.3389/fcvm.2022.903354. eCollection 2022.
3
Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib.与表皮生长因子受体抑制剂奥希替尼相关的心力衰竭
JACC CardioOncol. 2020 Mar 17;2(1):119-122. doi: 10.1016/j.jaccao.2020.01.003. eCollection 2020 Mar.
4
Cardiac Adverse Events in -Mutated Non-Small Cell Lung Cancer Treated With Osimertinib.奥希替尼治疗携带EGFR突变的非小细胞肺癌患者的心脏不良事件
JACC CardioOncol. 2020 Mar 17;2(1):1-10. doi: 10.1016/j.jaccao.2020.02.003. eCollection 2020 Mar.
5
Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).奥希替尼所致心脏毒性：对美国食品药品监督管理局不良事件报告系统（FAERS）的回顾性分析
JACC CardioOncol. 2019 Dec 17;1(2):172-178. doi: 10.1016/j.jaccao.2019.10.006. eCollection 2019 Dec.
6
Osimertinib-Induced Cardiomyopathy.奥希替尼诱发的心肌病。
JACC Case Rep. 2020 Apr 1;2(4):641-645. doi: 10.1016/j.jaccas.2019.12.038. eCollection 2020 Apr.
7
Case Report: QT Prolongation and Abortive Sudden Death Observed in an 85-Year-Old Female Patient With Advanced Lung Cancer Treated With Tyrosine Kinase Inhibitor Osimertinib.病例报告：在一名接受酪氨酸激酶抑制剂奥希替尼治疗的85岁晚期肺癌女性患者中观察到QT间期延长及猝死未遂情况。
Front Cardiovasc Med. 2021 Mar 19;8:655808. doi: 10.3389/fcvm.2021.655808. eCollection 2021.
8
Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma.奥希替尼诱发一名晚期肺腺癌患者出现心力衰竭伴QT间期延长及尖端扭转型室速。
Int Cancer Conf J. 2020 Oct 15;10(1):68-71. doi: 10.1007/s13691-020-00450-2. eCollection 2021 Jan.
9
Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease.表皮生长因子受体在生理与疾病中的表达及功能
Physiol Rev. 2016 Jul;96(3):1025-1069. doi: 10.1152/physrev.00030.2015.
10
Osimertinib induced cardiomyopathy: A case report.奥希替尼诱发的心肌病：一例报告。
Medicine (Baltimore). 2020 Sep 25;99(39):e22301. doi: 10.1097/MD.0000000000022301.
Zotero 插件